Article
Multidisciplinary Sciences
Sudpreeda Chainitikun, Sadia Saleem, Bora Lim, Vicente Valero, Naoto T. Ueno
Summary: The review focuses on the development of systemic treatment of IBC from the past to the present, including chemotherapy and targeted therapies. The effects on pathologic complete response (pCR), survival outcomes, predictive markers, and adverse events of these therapies are discussed, along with current standard treatment stratified by molecular subtypes. The future trend of systemic therapy, including immunotherapy and ongoing IBC clinical trials, is also addressed.
JOURNAL OF ADVANCED RESEARCH
(2021)
Article
Nanoscience & Nanotechnology
Xiaoxi Wang, Xueqin Zhu, Bingyu Li, Xiuyu Wei, Yalan Chen, Yun Zhang, Yan Wang, Wenyan Zhang, Sijia Liu, Zimai Liu, Wenjie Zhai, Pingping Zhu, Yanfeng Gao, Zhenzhen Chen
Summary: An intelligent bionic nanoplatform combining targeted therapy with immunotherapy was developed to treat triple-negative breast cancer. In vitro and in vivo experiments demonstrated that this nanoplatform effectively inhibited the growth and metastasis of breast cancer and triggered an anti-tumor immune response.
ACS APPLIED MATERIALS & INTERFACES
(2022)
Article
Nanoscience & Nanotechnology
Lin Li, Jian Fu, Xingyue Wang, Qiaoqi Chen, Wei Zhang, Yang Cao, Haitao Ran
Summary: The nanoplatelets derived from platelet membranes served as contrast agents for multimodal imaging and effectively enhanced the therapeutic performance in treating breast cancer.
ACS APPLIED MATERIALS & INTERFACES
(2021)
Article
Engineering, Environmental
Tianfu Zhang, Yanlin Deng, Yang Sylvia Liu, Song Lin Chua, Ben Zhong Tang, Bee Luan Khoo
Summary: Researchers developed a novel combination strategy of photodynamic therapy and chemotherapy, which effectively killed bacteria in a three-dimensional bladder cancer model. This strategy has the potential to improve treatment efficacy and allow for treatment guided by fluorescence imaging in vivo.
CHEMICAL ENGINEERING JOURNAL
(2022)
Article
Pharmacology & Pharmacy
Nicola D'Avanzo, Giulia Torrieri, Patricia Figueiredo, Christian Celia, Donatella Paolino, Alexandra Correia, Karina Moslova, Tambet Teesalu, Massimo Fresta, Helder A. Santos
Summary: This study developed a targeting nanoparticle by conjugating LinTT1 peptide on liposomes, enhancing the cytotoxic effects of DOX and SRF on breast cancer cellular models. The functionalization of liposomes increased their interaction with breast cancer spheroids. Interaction studies with M2 macrophages suggest the potential use of these liposomes to enrich hypoxic tumor areas.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2021)
Review
Cell Biology
Kunrui Zhu, Yanqi Wu, Ping He, Yu Fan, Xiaorong Zhong, Hong Zheng, Ting Luo
Summary: Phosphatidylinositol 3-kinase (PI3K), protein kinase B (PKB/AKT) and mechanistic target of rapamycin (mTOR) (PAM) pathways play important roles in breast tumorigenesis and offer potential targets for cancer therapy.
Article
Biochemistry & Molecular Biology
Kristie H. Lau, Alexandra M. Tan, Yihui Shi
Summary: This article discusses the incidence and classification of breast cancer in the United States, and explores the main treatment methods, including surgery, radiation therapy, chemotherapy, endocrine therapy, and targeted therapy. It also highlights the research focus on triple-negative breast cancer treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Oncology
Xiaolu Sun, Kuai Liu, Shuli Lu, Weina He, Zixiu Du
Summary: Breast cancer is a molecularly diverse disease with heterogeneity. Targeted therapy and immunotherapy offer solutions to improve prognosis and address drug resistance. Molecular classifications are important for clinical diagnosis and treatment strategies differ according to the molecular subtype. Targeted therapy and immunotherapy provide hope for the treatment of breast cancer.
Review
Biochemistry & Molecular Biology
Abygail G. Chapdelaine, Gongqin Sun
Summary: Triple negative breast cancer (TNBC) is a heterogeneous group of breast cancers characterized by their lack of estrogen receptors, progesterone receptors, and the HER2 receptor. Developing targeted therapies for TNBC has been a major challenge due to its heterogeneity, and its treatment still largely relies on surgery, radiation therapy, and chemotherapy. Accumulating evidence supports TNBCs as multi-driver cancers, and a strategy designed to generate mechanism-based combination targeted therapies for TNBC is discussed.
Article
Pharmacology & Pharmacy
Balazs Vari, Levente Dokus, Adina Borbely, Aniko Gaal, Diana Vari-Mezo, Ivan Randelovic, Anna Solyom-Tisza, Zoltan Varga, Norbert Szoboszlai, Gabor Mezo, Jozsef Tovari
Summary: Chemotherapy remains an important treatment for various types of tumors, but its poor prognosis is often due to metastases. PEGylated liposomes with CREKA targeting moiety have been widely used as therapeutic agents in highly metastatic experimental models. In this study, we designed different liposome formulations with varying amounts of targeting moieties attached to their DSPE-PEG molecules. We also developed a new tumor-homing pentapeptide (SREKA) and a novel conjugation strategy between SREKA and DSPE-PEGs. Our results showed that SREKA-liposomes exhibited similar characteristics and tumor-homing capabilities to CREKA-liposomes, but had higher production yield and better stability upon conjugation. SREKA-liposomes effectively inhibited primary tumor growth, reduced metastasis incidence, and improved the survival rate of tumor-bearing mice. Additionally, the amount of targeting moiety attached to DSPE-PEGs played a crucial role in the stability, toxicity, and targeting of the liposomes.
Review
Biochemistry & Molecular Biology
Meng Lan, Wenping Lu, Tengteng Zou, Lihong Li, Fengjie Liu, Tiange Cai, Yu Cai
Summary: Tumor cells, inflammatory cells, and chemical factors collaborate to form the inflammatory tumor microenvironment, which plays a crucial role in the development of breast cancer. Inflammatory microenvironment contributes to breast cancer growth, metastasis, drug resistance, and angiogenesis through multifactorial mechanisms. Nano-drug delivery system (NDDS) is a popular topic for optimizing tumor targeting drugs, enhancing bioavailability, reducing drug dose, and eliminating off-target side effects.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2021)
Review
Biochemistry & Molecular Biology
Isaiah A. Edwards, Flavia De Carlo, Juliana Sitta, William Varner, Candace M. Howard, Pier Paolo Claudio
Summary: The response to cancer treatments varies greatly and can cause severe side effects. Researchers aim to develop new treatments that can specifically target and kill tumor cells with minimal drug dosage. Despite advancements in drug formulations and active targeting, the desired clinical outcome has not been achieved. This review discusses the current classification and standard of care for breast cancer, as well as the use of nanomedicine and ultrasound-responsive carriers in preclinical studies for drug and gene delivery to breast cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Oncology
Hongnan Mo, Binghe Xu
Summary: Triple-negative breast cancer is the most aggressive subtype of breast cancer, where chemotherapy shows activity in some patients but drug resistance remains a challenge. Significant progress in genetic analysis has led to the identification of novel targets and improved precision in therapeutic interventions, advancing treatment strategies.
FRONTIERS OF MEDICINE
(2021)
Review
Oncology
Shuangli Zhu, Yuze Wu, Bin Song, Ming Yi, Yuheng Yan, Qi Mei, Kongming Wu
Summary: Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, lacks expression of estrogen receptor, progesterone receptor, and HER2. Although chemotherapy is the main treatment for TNBC, its effectiveness is limited. Various targeted therapies, including inhibitors of the PI3K/AKT/mTOR pathway, epidermal growth factor receptor inhibitors, Notch inhibitors, poly ADP-ribose polymerase inhibitors, and antibody-drug conjugates, have emerged. Additionally, immune checkpoint inhibitors such as pembrolizumab, atezolizumab, and durvalumab, are being extensively investigated. This review summarizes recent advances in targeted therapy and immunotherapy in TNBC, aiming to serve as a reference for future development of personalized treatment for TNBC patients.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2023)
Review
Oncology
Mayassa J. Bou-Dargham, Sophia Draughon, Vance Cantrell, Zahraa I. Khamis, Qing-Xiang Amy Sang
Summary: Breast cancer treatment has advanced significantly, with targeted therapies and immunotherapy showing promise. Personalized and combination therapies are expected to enhance treatment efficacy and improve patient survival rates.
Article
Oncology
Takashi Semba, Xiaoping Wang, Xuemei Xie, Evan N. Cohen, James M. Reuben, Kevin N. Dalby, James P. Long, Lan Thi Hanh Phi, Debu Tripathy, Naoto T. Ueno
Summary: The study identified that high phosphorylated JNK level in TNBC is associated with increased Treg infiltration. Inhibition of JNK signaling led to reduced tumor growth and Treg infiltration, and increased CD8(+) T cell infiltration, possibly through suppression of CCL2 secretion. This suggests that targeting the JNK/C-JUN/CCL2 axis may offer new therapeutic strategies for combating the aggressiveness of TNBC.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
(2022)
Article
Oncology
Charlotte Rypens, Francois Bertucci, Pascal Finetti, Fredika Robertson, Sandra Fernandez, Naoto Ueno, Wendy A. Woodward, Kenneth Van Golen, Peter Vermeulen, Luc Dirix, Patrice Viens, Daniel Birnbaum, Gayathri R. Devi, Massimo Cristofanilli, Steven Van Laere
Summary: In this study, the transcriptome of a series of inflammatory breast cancer (IBC) preclinical models was evaluated and compared to patient samples. It was found that the IBC preclinical models are predominantly estrogen receptor-negative and of the basal-like subtype, which is similar to the molecular characteristics observed in patients. The study also revealed important roles for cell proliferation, MYC transcriptional activity, and TNF alpha/NF kappa B in IBC biology.
Review
Biochemistry & Molecular Biology
Sridevi Addanki, Salyna Meas, Vanessa Nicole Sarli, Balraj Singh, Anthony Lucci
Summary: Liquid biopsies are a non-invasive method for detecting cancer biomarkers through a simple blood draw. These circulating markers have significant prospects in evaluating patients' prognosis, monitoring therapy response, and developing precision medicine.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Editorial Material
Oncology
Clara R. Farley, Shelby Irwin, Taiwo Adesoye, Susie X. Sun, Sarah M. DeSnyder, Anthony Lucci, Simona F. Shaitelman, Edward I. Chang, Naoto T. Ueno, Wendy A. Woodward, Mediget Teshome
ANNALS OF SURGICAL ONCOLOGY
(2022)
Letter
Oncology
Steven J. Chmura, Wendy A. Woodward, Julia R. White
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Evan N. Cohen, Gitanjali Jayachandran, Richard G. Moore, Massimo Cristofanilli, Julie E. Lang, Joseph D. Khoury, Michael F. Press, Kyu Kwang Kim, Negar Khazan, Qiang Zhang, Youbin Zhang, Pushpinder Kaur, Roberta Guzman, Michael C. Miller, James M. Reuben, Naoto T. Ueno
Summary: This study tested the ability of a semi-automated device to capture CTCs from peripheral blood based on cell size and deformability, and found methods to evaluate the captured CTCs. The data from this study were used to support the FDA classification request for the device, and demonstrated its effectiveness in capturing and evaluating CTCs from MBC patients.
Article
Oncology
Francois Richard, Maxim De Schepper, Marion Maetens, Sophia Leduc, Edoardo Isnaldi, Tatjana Geukens, Karen Van Baelen, Ha-Linh Nguyen, Peter Vermeulen, Steven Van Laere, Francois Bertucci, Naoto Ueno, Luc Dirix, Giuseppe Floris, Elia Biganzoli, Christine Desmedt
Summary: In this study, the genomic alterations in primary and metastatic tumor samples from patients with metastatic inflammatory breast cancer (IBC) and non-IBC were compared. Higher frequency of AURKA amplification was observed in IBC, which was associated with increased AURKA mRNA expression and worse prognosis. These findings should be further investigated considering the existence of AURKA inhibitors.
Editorial Material
Oncology
Wendy A. Woodward, Melissa P. Mitchell
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
(2023)
Article
Medicine, General & Internal
Alshaimaa Tarek, Hossam Taha Mohamed, Aya Ali El-Sharkawy, Shrouk Khalaf El-Sayed, Jon Mark Hirshon, Wendy A. Woodward, Mohamed El-Shinawi, Mona Mostafa Mohamed
Summary: By comparing the gene expression profiles of matrisome and adhesome in non-IBC and IBC tissues, as well as the secretory inflammatory mediators in patient-derived explants, we found that these genes and cytokines play a significant role in the metastasis of inflammatory breast cancer.
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE
(2023)
Article
Oncology
Nour Abuhadra, Ryan Sun, Clinton Yam, Gaiane M. Rauch, Qingqing Ding, Bora Lim, Alastair M. Thompson, Elizabeth A. Mittendorf, Beatriz E. Adrada, Senthil Damodaran, Kiran Virani, Jason White, Elizabeth Ravenberg, Jia Sun, Jaihee Choi, Rosalind Candelaria, Banu Arun, Naoto T. Ueno, Lumarie Santiago, Sadia Saleem, Sausan Abouharb, Rashmi K. Murthy, Nuhad Ibrahim, Aysegul Sahin, Vicente Valero, William Fraser Symmans, Jennifer K. Litton, Debu Tripathy, Stacy Moulder, Lei Huo
Summary: In this study, clinicopathologic features, including sTILs, Ki-67, PD-L1, and androgen receptor, were evaluated in 408 early-stage TNBC patients. Integrating high Ki-67 (>35%) and high sTILs (≥20%) in a computed response score model predicted a pCR rate of 65%. This model has the potential to refine patient selection for neoadjuvant clinical trials evaluating de-escalation strategies.
Article
Oncology
Balraj Singh, Vanessa N. Sarli, Ryan D. Milligan, Hannah E. Kinne, Anna Shamsnia, Laura J. Washburn, Sridevi Addanki, Anthony Lucci
Summary: We treated highly metabolically adaptable triple-negative inflammatory breast cancer cells with JQ1 and found that it inhibited therapy-resistant cells. Although JQ1 couldn't kill these resistant cells, it sensitized them to treatment with doxorubicin and paclitaxel. Additionally, JQ1 reduced PD-L1 protein levels, indicating a potential improvement in immunotherapy response.
Article
Oncology
Evan N. Cohen, Gitanjali Jayachandran, Hui Gao, Phillip Peabody, Heather B. McBride, Franklin D. Alvarez, Megumi Kai, Juhee Song, Yu Shen, Jie S. Willey, Bora Lim, Vicente Valero, Naoto T. Ueno, James M. Reuben
Summary: Circulating tumor cells (CTCs) are valuable indicators for managing metastatic breast cancer (MBC). Enrichment of CTCs based on size and deformability can capture a wider range of tumor cells, providing a complementary approach to tissue biopsy. A longitudinal study using a microcavity array showed that the shift from epithelial CTCs to those with a mesenchymal expression pattern is associated with worse clinical outcomes.
Article
Biochemistry & Molecular Biology
Xuemei Xie, Jangsoon Lee, Jon A. Fuson, Huey Liu, Toshiaki Iwase, Kyuson Yun, Cori Margain, Debu Tripathy, Naoto T. Ueno
Summary: In this study, RNAi screening and pathway analysis identified 135 potential kinase targets whose inhibition enhanced the antiproliferation effect of eribulin in TNBC cells. The PI3K/Akt/mTOR and MAPK/JNK pathways emerged as the top candidates. Combination of eribulin with copanlisib, everolimus, trametinib, and JNK-IN-8 produced strong synergistic antiproliferative effects, with the PI3K and mTOR inhibitors showing the most potent effects in vitro.
Article
Oncology
Manasa Gadde, Melika Mehrabi-Dehdezi, Bisrat G. Debeb, Wendy A. Woodward, Marissa Nichole Rylander
Summary: Macrophages, specifically tumor-associated macrophages (TAMs), play a vital role in the progression of inflammatory breast cancer (IBC). This study presents a 3D in vitro microfluidic IBC platform that incorporates TAMs, IBC cells, and endothelial cells. The inclusion of TAMs in the platform led to an increase in the formation of new blood vessel sprouts and enhanced permeability of the endothelium. Interestingly, platforms containing THP-1 M1 or M2 macrophages exhibited significantly greater porosity in the extracellular matrix compared to platforms containing THP-1 M0 and MDA-IBC3 cells alone. Cytokine analysis revealed selective increases in IL-8 and MMP9 secretion when macrophages were cultured in the platforms. Notably, intravasation of tumor cells into the vessels was observed exclusively in the platform containing MDA-IBC3 and M0 macrophages.
Article
Oncology
Hiroko Masuda, Kenichi Harano, Sakiko Miura, Ying Wang, Yuko Hirota, Oi Harada, Mohit Kumar Jolly, Yuki Matsunaga, Bora Lim, Anita L. Wood, Napa Parinyanitikul, Hee Jin Lee, Gyungyub Gong, Jason T. George, Herbert Levine, Jangsoon Lee, Xiaoping Wang, Anthony Lucci, Arvind Rao, Brock L. Schweitzer, O. Rayne Lawrence, Robert S. Seitz, Stephan W. Morris, David R. Hout, Seigo Nakamura, Savitri Krishnamurthy, Naoto T. Ueno
Summary: The study found that TNBC molecular subtype and IM signature frequently change after NST, and the results suggest that EMT is promoted in the changed subtypes.
JCO PRECISION ONCOLOGY
(2022)
